Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus rating of "Buy" by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $18.63.

TRVI has been the topic of several analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. Oppenheimer boosted their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday. HC Wainwright started coverage on Trevi Therapeutics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price objective for the company. Finally, Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the company from $9.00 to $29.00 in a research report on Monday, March 10th.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares of the company's stock, valued at $519,075. This represents a 51.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $1,403,599.54. The trade was a 2.41% decrease in their position. The disclosure for this sale can be found here. 18.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Trevi Therapeutics by 14.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock worth $713,000 after buying an additional 22,145 shares during the period. Renaissance Technologies LLC boosted its position in shares of Trevi Therapeutics by 42.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock worth $414,000 after buying an additional 29,700 shares during the period. American Century Companies Inc. boosted its position in shares of Trevi Therapeutics by 44.7% in the fourth quarter. American Century Companies Inc. now owns 78,143 shares of the company's stock worth $322,000 after buying an additional 24,153 shares during the period. Northern Trust Corp boosted its position in shares of Trevi Therapeutics by 11.3% in the fourth quarter. Northern Trust Corp now owns 482,815 shares of the company's stock worth $1,989,000 after buying an additional 49,173 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Trevi Therapeutics by 120.5% in the fourth quarter. JPMorgan Chase & Co. now owns 221,664 shares of the company's stock worth $913,000 after buying an additional 121,147 shares during the period. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Up 10.6%

NASDAQ:TRVI traded up $0.63 during mid-day trading on Friday, reaching $6.58. 9,057,585 shares of the stock were exchanged, compared to its average volume of 1,301,563. The company has a 50 day simple moving average of $6.23 and a 200-day simple moving average of $4.93. The stock has a market capitalization of $657.30 million, a P/E ratio of -14.95 and a beta of 0.59. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.48.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. As a group, research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.